Important note: Information in this article was accurate in June 2000. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; Monday, June 5, 2000
Prepared by AIDS Weekly editors from staff and other reports
It works even better in patients with HIV-1 N88S mutations, scientists say.
"Amprenavir (Agenerase, 141-W94, VX-478) is a HIV-1 protease inhibitor (PRI) recently approved for the treatment of HIV-1 infection in the United States," R. Ziermann and associates noted.
Four major protease inhibitors are presently used in antiretroviral therapy, these include saquinavir, indinavir, ritonavir, and nelfinavir. Of these four, nelfinavir and indinavir are prescribed the most often, according to the researchers. It was these two drugs that Ziermann's group investigated for viral cross-resistance with amprenavir.
"Unexpectedly, a dramatic increase in susceptibility (2.5- to 12.5-fold) was observed with 20 of 312 (6.4%) patient viruses analyzed," Ziermann et al. said.
But more interestingly, the most hypersensitivity to amprenavir was seen in patients with an HIV mutation in the N88S protease. "All viruses that carried the N88S mutation were hypersensitive to amprenavir," investigators reported ("A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir," J Virol 2000 May;74(9):4414-9.
Ziermann and colleagues concluded, "The presence of the N88S mutation and associated amprenavir hypersensitivity may be useful in predicting an improved clinical response to amprenavir salvage therapy."
Search the www.NewsRx.com online database for 32 more articles about amprenevir.
The corresponding author for this study is N.T. Parkin, 270 E. Grand Avenue, South San Francisco, California 94080, USA.
Key points reported in this study are:
This article was prepared by AIDS Weekly editors from staff and other reports.
000605
AW000602
Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.